Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Japanese Patients with Advanced HCC
NCT03586973Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Takeda. Primary endpoint: 24-Week Progression-Free Survival Rate. Started Aug 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03586973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586973.